News ASCO26: Lilly's Retevmo aces early-stage lung cancer trial Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.
Oncology What will ASCO 2026 reveal about oncology innovation’s new g... The next leaders in oncology will be the ones built to adapt in real time.
News Late-breakers to look out for at ASCO 2026 ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
News FDA clears first drug for MCT8 deficiency Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.